Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT

EBV-associated post-transplant lymphoproliferative disease (PTLD) remains an important complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT). We retrospectively analysed the incidence and risk factors for EBV reactivation in 186 adult patients undergoing consecutive allo-HS...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Bone Marrow Transplant
Hlavní autoři: Burns, D M, Rana, S, Martin, E, Nagra, S, Ward, J, Osman, H, Bell, A I, Moss, P, Russell, N H, Craddock, C F, Fox, C P, Chaganti, S
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2016
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4880046/
https://ncbi.nlm.nih.gov/pubmed/26901708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2016.19
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky